{
    "clinical_study": {
        "@rank": "47119", 
        "brief_summary": {
            "textblock": "To evaluate the safety and immunogenicity of a combination of microparticulate monovalent\n      HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent\n      HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in\n      intermediate or higher risk HIV-negative volunteers."
        }, 
        "brief_title": "A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Volunteers receive one of two schedules of vaccines or placebo administered at days 0, 28,\n      and 168. Specifically, group 1 receives oral microparticulate monovalent vaccine over 3\n      consecutive days on days 0, 1, and 2, and 28, 29, and 30, with the intramuscular monovalent\n      vaccine given on day 168. Group 2 receives the intramuscular vaccine first, on day 0,\n      followed by the oral form given on days 28, 29, and 30 and 168, 169, and 170. Volunteers are\n      followed for 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Volunteers must have:\n\n          -  Normal history and physical exam.\n\n          -  HIV negativity.\n\n          -  CD4 count >= 400 cells/mm3.\n\n          -  Intermediate or high risk sexual behavior or a history of injection drug use within\n             12 months prior to study entry.\n\n          -  Normal urine dipstick with esterase and nitrite.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Volunteers with the following symptoms or conditions are excluded:\n\n          -  Active tuberculosis.\n\n          -  Occupational or other responsibilities that would prevent completion of study.\n\n        Volunteers with the following prior conditions are excluded:\n\n          -  History of immunodeficiency, chronic illness, autoimmune disease, or use of\n             immunosuppressive medications.\n\n          -  Psychiatric, medical, or substance abuse problems within the past 6 months that would\n             affect ability to participate in study.\n\n          -  History of anaphylaxis or other serious adverse reactions to vaccines.\n\n          -  History of inflammatory gastrointestinal disease, celiac disease, or intestinal\n             malignancy.\n\n          -  Acute gastroenteritis or gastrointestinal surgery within the past 12 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Live or attenuated vaccine within the past 60 days.\n\n          -  Illicit or experimental agents within the past 30 days. Intermediate or high risk\n             sexual behavior. Injection drug use within the past 12 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002428", 
            "org_study_id": "091", 
            "secondary_id": "UBI V106"
        }, 
        "intervention": [
            {
                "intervention_name": "HIV-1 Peptide Vaccine, Microparticulate Monovalent", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "keyword": [
            "Vaccines, Synthetic", 
            "HIV-1", 
            "HIV Envelope Protein gp120", 
            "AIDS Vaccines", 
            "HIV Seronegativity"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94110"
                }, 
                "name": "Univ of California at San Francisco Gen Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "11311997", 
            "citation": "Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine. 2001 Apr 30;19(23-24):3033-42."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002428"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "United Biomedical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Univ of California at San Francisco Gen Hosp": "37.775 -122.419"
    }
}